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Abstract
Background: There is no standard adjuvant chemotherapy to prevent recurrent cholangiocarcinoma (CCA), a rare cancer with poor 
prognosis. We assessed the efficacy and safety of GEMOX on intrahepatic and hilar CCA with high-risk factors after curative surgery.
Patients and Methods: Twenty two patients (mean age: 57 years old) with CCA received 6 cycles of GEMOX: gemcitabine 1,000 mg/m² 
on day 1 and oxaliplatin 85 mg/m² on day 2, q3w after a curative surgery.
Results: All patients completed 6 cycles of GEMOX. EGFR membranous expression was present in 20 CCA. The 5-year survival 
rate was 56% (CI 95%: 25.7–85.4); 2-year disease free survival rate was 28% (CI 95%: 3.4–52.6). Median time to progression was 
15 months. The rate of recurrence after surgery and chemotherapy was 63% (14/22). Two patients died of disease progression. Twelve 
patients received cetuximab/GEMOX at the time of relapse. Six died after 12 months (9–48 months), three are still alive suggesting a 
clinical applicability of EGFR inhibitors in CCA.
Conclusion: Adjuvant chemotherapy with GEMOX alone seems ineffective in intrahepatic and hilar CCA with a high risk of relapse. 
Additional studies including targeted therapies to circumvent such poor chemosensitivity are needed.
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Introduction
Patients with cholangiocarcinoma (CAA) have extremely 
poor  prognosis  with  an  average  5-year  survival  rate 
of  5%–10%.1 Among  the  clinicopathologic  factors 
influencing the survival after surgical treatment, cura-
tive surgery, lymph node metastases, tumor size and 
cancer-free margin are the most predictive factors.2–8 
Recently, in a large series of CCA, multivariate anal-
ysis showed that EGFR expression was a risk factor 
for recurrence of intrahepatic CCA9 with a five-year 
survival rate at around 20% and in hilar bile duct 
cancer, after curative resection, 40% of the patients 
had disease recurrence.8 In these patients with high 
risk factors, adjuvant therapy may play a role in pro-
longing survival. The aim of this pilot study was to 
assess the efficacy and safety of adjuvant chemother-
apy (GEMOX) in high-risk patients with intrahepatic 
and hilar CAA after curative surgery.
patients and Methods
Patients and treatment
Patients were eligible for entry into this pilot study if 
they fulfilled the following criteria: age 18 years, 
Karnofsky Performance Status (KPS)  80%, histologi-
cally confirmed diagnosis of  CCA tumor tissue available 
for immunohistochemical EGFR detection and curative 
surgery. Laboratory acceptance parameters included 
an absolute neutrophil count of  1,500 cells/µL, a 
platelet count of 100,000 cells/µL, a serum creatinine 
level  130 µmol/L and a total serum bilirubin level  3 × 
the upper normal limit. The protocol was approved by 
the institutional review board (Centre Hepato-Biliaire, 
Villejuif,  France)  and  was  conducted  according  to 
the principles of the Declaration of Helsinski and the 
rules  of  good  clinical  practices.  Informed  consent 
was obtained from all patients. Twenty two Cauca-
sian patients (10 women, 12 men, mean age: 57 years 
old, range: 30–73, KPS  80%) were treated in our 
institution for an intrahepatic (n = 10) or hilar CCA 
(n = 12). They had one or more dismal prognostic 
factors: lymph node involvement, positive histologic 
margins, pernervous and/or vascular tumoral embols. 
All patients received 6 cycles of GEMOX for 5 weeks 
after they had undergone curative surgery. All patients 
had  histologically  proven  EGFR  expressing  CCA. 
Gemcitabine was given at an initial dose of 1000 mg/m² 
as a 10 mg/m²/min infusion on day 1 and oxaliplatin 
85 mg/m² as a 4-h infusion on day 2. A prophylactic 
antiemetic treatment comprising 5-hydroxytryptamine 
type 3 receptor antagonists and dexamethasone was 
given. GEMOX was repeated every 3 weeks if the 
neutrophil count was 1500 cells/µL and the platelet 
count was 100 000/µL.
immunohistochemistry
Immunohistochemical  detection  of  EGFR  was  per-
formed using EGFR antibodies (31G7 clone and/or 
2-18C9 clone) on 4 µm thick deparaffinized tumor 
sections before any chemotherapy. Only cell membrane 
staining  was  considered  to  be  specific.  EGFR  sta-
tus was considered positive when  = 1% of tumor 
cells  showed  complete  membranous  staining.  The 
percentage of tumor cells expressing EGF-R was semi-
quantitatively assessed, and the intensity of staining 
was scored as follows: 0: no staining; 1+: weak, 2+: 
moderate;  3+:  strong. When  staining  intensity  was 
heterogeneous, the highest intensity was retained as 
the score. Hepatocytes and peripheral nerves served as 
positive internal controls and positive (HT29 cell line) 
and negative (CAM-1 cell line) external controls were 
included (Fig. 3).
Assessment of efficacy and toxicity
The primary endpoint of the study was disease free 
survival. The secondary endpoint was overall survival. 
CT scans were performed at base line and every three 
cycles. After the treatment, CT scans were performed 
every three months until progression. Toxicity was 
graded according to the National Cancer Institute-
Common Toxicity Criteria (NCI CTC) (version 2.0) 
and evaluated at each cycle.
statistical analysis
The Kaplan-Meier method was used to estimate overall 
and progression-free survival outcomes. Time to pro-
gression was calculated from the first day of GEMOX 
administration until the date when first progression of 
disease was observed. Overall survival was calculated 
from the first day of GEMOX administration until the 
date of death or last follow-up.
Results
Efficacy
Between 2000 and 2005, 22 patients with histologi-
cally confirmed CCA underwent curative surgery and geMOX after curative surgery in patients with CCA
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lymphadenectomy. Patient characteristics are summarized 
in Table 1. The different surgical procedures included 
7 right hepatectomies extended to segments 4 and 1; 8 
left hepatectomies extended to segment 1; 5 left hepa-
tectomies extended to segments 4 and 1; 1 right hepa-
tectomy extended to segments 4; 1 left hepatectomy 
extended to segment 1, 4. Hepatic resection was con-
sidered as curative (R0) when there was no evidence 
of microscopic disease (8 patients). Resection was R1 
(only microscopic disease) for 14 patients.
The  men/women  ratio  was  12/10.  The  median 
age of the patients was 57 years (range 30–73). The 
median follow-up period was 30 months (range 8–66). 
Immunohistochemical results were available for 21 of 
the 22 patients according to the results of positive con-
trols (Table 2). For the latest tumor, positive internal 
controls were always negative in spite of several tests. 
EGFR membranous expression was present in 20 CCA 
(95%) and one tumor was negative. If a 10% cut-
off  was  chosen,  15  tumors  out  of  21  (76%)  were 
EGFR-positive. EGFR was mainly overexpressed in 
the moderately and/or poorly differentiated tumors, 
whereas only two well-differentiated cases showed 
EGFR overexpression.
All  22  patients  completed  6  cycles  of  adjuvant 
GEMOX. The 5-year survival rate was 56% (CI 95%: 
25.7–85.4) (Fig. 1) and the 2-year disease free survival 
rate was 28% (CI 95%: 3.4–52.6) (Fig. 2). The median 
time to progression was 15 months: 10 months for hilar 
CCA (n = 12), and 15 months for intrahepatic CCA 
(n = 10). Eight patients (hilar = 4, intrahepatic n = 4) 
had no progression of the disease. These 8 patients 
Table 1. Patient characteristics.
characteristics  
number of patients 22
Age (years)
  Median (range) 57 (30–73)
Gender
  Men/Women 12/10
performance status (Karnofsky %)  90
cholangiocarcinoma
  Extra hepatic (Klatskin) 12
  intrahepatic 10
TnM stage
  pT2 9
  pT3 9
  pT4 4
surgical treatment
  Partial hepatectomy right/left 10/12
Indications of adjuvant treatment
  Positive margins 14
  negative margins 8
  n+ 7
  Tumoral embol: perinervous/vascular 10/10
Complete response 8
Progression disease 14
One patient could have more than one indication for adjuvant treatment.
Table 2. EGFR protein expression.
patient n° eGFR protein 
expression  
(% of positive tumor 
cells/intensity)
Grade of 
differentiation
1 50%/2+ Moderate
2 20%/2+ Moderate
3 100%/2+ Poor
4 30%/1+ Poor
5 40%/2+ Poor
6 0% Moderate
7 100%/2+ Well
8 100%/2+ Poor
9 5%/1+ Poor
10 70%/2+ Well
11 1%/2+ Moderate
12 5%/1+ Moderate
13 1%/1+ Well
14 1%/2+ Well
15 30%/1+ Moderate
16 20%/2+ Moderate
17 70%/2+ Moderate
18 30%/3+ Poor
19 70%/2+ Poor
20 ne Moderate
21 30%/2+ Poor
22 30%/2+ Well
Abbreviation: ne, not evaluable.Paule et al
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had no lymph node metastases but 5 had a positive 
histologic margin (R1). The rate of recurrence after 
surgery and chemotherapy was 63% (14/22). The recur-
rences occurred in the liver, peritoneum and metastatic 
lymph  nodes  (hilar  and  celiac  lymph  nodes).  Two 
patients died 13 and 29 months after the beginning of 
the treatment due to disease progression. After relapse, 
a second line of chemotherapy adding cetuximab to 
GEMOX was performed for 12 patients. Six patients 
died after 12 months on average (range: 9–48 months) 
after cetuximab onset. A third line of chemotherapy 
was administered to 6 patients, 3 of whom are still 
alive. (Table 3).
safety
All 22 patients completed 6 cycles of GEMOX. Treat-
ment was well tolerated. No reductions in gemcitabine 
and  oxaliplatin  doses  or  treatment  delays  were 
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Figure 2. Progression free survival in high risk patients.
Figure 1. Overall survival in high risk patients.
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
Months
100%
67%
56%
100
80
60
40
20
12 24 36 60 48 72
0
0geMOX after curative surgery in patients with CCA
Clinical Medicine: Oncology 2009:3  125
necessary. All patients were assessable for toxicity. 
There was no treatment-related death, anemia, neutro-
penia, thrombocytopenia, or neurotoxicity. Acne-like 
rash was observed in all patients treated with cetux-
imab and occurred within the first three weeks of the 
treatment.
Discussion
Our study analyses the impact of adjuvant chemotherapy 
in hilar and intrahepatic CCA after curative surgery. 
All patients had 1 or more factors of poor prognosis 
such as positive margin, lymph node metastases, lym-
phatic vessel invasion or perineural invasion and 95% 
of  tumors  had  membranous  expression  of  EGFR. 
In our study, we used GEMOX after curative surgery 
since  regimens  including  gemcitabine  were  found 
to be active and safe for the patients with advanced 
biliary tract carcinoma.10–15 Even if well tolerated, the 
adjuvant GEMOX regimen alone does not seem to 
be very effective in our high-risk patients reaching 
a  2-year  progression  free  survival  rate  of  28%. 
In comparison, a 3-year disease-free survival rate of 
43% has been reported in resected patients with hilar 
or intrahepatic CCA4,8 and the five-year survival rate 
for  intrahepatic  CCA  patients  with  EGFR-positive 
tumors was low at around 20%.9 A possible limited 
benefit of GEMOX may be due to EGFR expression 
that has been associated with increasing resistance 
to chemotherapy.16,17 However, there were 8 patients 
(4  intrahepatic  and  4  hilar  CCA)  with  no  tumor 
progression, probably due to the fact that these patients 
had no lymph node metastasis which is a significant 
risk  factor  of  tumor  recurrence7  Furthermore,  in 
hilar CCA without lymph node involvement, major 
hepatectomy can offer long term survival even in the 
case of R1 resection.8
The median survival is not reached in our study 
because 12 patients received additional treatment with 
cetuximab/GEMOX at the time of relapse. Since add-
ing cetuximab circumvents tumor resistance to chemo-
therapy, the tumor may respond to a therapy on which 
it  had  previously  progressed.  This  mechanism  has 
previously been documented in metastatic colorectal 
cancer  or  in  recurrent  head  and  neck  cancer.16,18 
In human CCA cell lines, the EGFR kinase inhibitors 
AG1478 or ZD1839 significantly suppress CCA cell 
growth.19 Recently, cetuximab or inhibitors of tyrosine 
kinase  have  been  used  clinically  in  intrahepatic 
CCA.20,21 Some case reports have been reported22,23 
and in patients with refractory advanced intra hepatic 
CCA, adding cetuximab to GEMOX circumvented 
tumor resistance to chemotherapy in some patients.21 
These studies suggest a clinical applicability of EGFR 
inhibitors in CCA. For improving the use of adjuvant 
GEMOX in EGFR positive CCA, drugs that target 
tumor cell—associated receptor tyrosine kinase might 
be useful in patients classified as high-risk.
conclusion
Given the results of the present study, we consider 
that six cycles of adjuvant GEMOX is not the optimal 
chemotherapy in patients with high risk factors. The 
limited benefit of GEMOX is possibly due to EGFR 
expression, because EGFR overexpression has been 
associated with more aggressive disease and increased 
resistance to chemotherapy. Our data may indicate the 
Anti-EGFR
Figure  3.  Anti-egFr  immunostaining  (31g7  monoclonal  antibody—
LsAB technique) with +++ positivity × 400.
Table 3. Outcome of the patients.
Disease related death 8
number of recurrent case 14
Liver 7
Peritoneum 1
Lymph node 6
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need for additional studies regarding the role of the 
target therapy in adjuvant treatment among certain 
subsets of CCA including those with EGFR-positive 
tumors.
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